Skip Navigation


JAC Advance Access first published online on May 30, 2006
This version published online on June 14, 2006
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkl184
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Supplementary Data
Right arrow All Versions of this Article:
58/2/418    most recent
dkl184v2
dkl184v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Coenen, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Coenen, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org
Revised April 12, 2006
Accepted April 16, 2006

Original article

European Surveillance of Antimicrobial Consumption (ESAC): outpatient macrolide, lincosamide and streptogramin (MLS) use in Europe

Samuel Coenen 1 * {dagger}, Matus Ferech 2 {dagger}, Surbhi Malhotra-Kumar 2, Erik Hendrickx 3, Carl Suetens 3, Herman Goossens 4, and on behalf of the ESAC Project Group {ddagger}

1 Department of General Practice, University of Antwerp, Antwerp, Belgium; Fund for Scientific Research--Flanders, Brussels, Belgium
2 Laboratory of Microbiology, University of Antwerp, Antwerp, Belgium
3 Unit of Epidemiology, Scientific Institute of Public Health, Brussels, Belgium
4 Laboratory of Microbiology, University of Antwerp, Antwerp, Belgium; Laboratory of Microbiology, Leiden University Medical Center, Leiden, The Netherlands

* To whom correspondence should be addressed.
Samuel Coenen, E-mail: samuel.coenen{at}ua.ac.be


  Abstract

Background: Data on outpatient macrolide, lincosamide and streptogramin (MLS) use in Europe were collected from 25 countries within the ESAC project, funded by DG SANCO of the European Commission, using the WHO ATC/DDD methodology.

Methods: For the period 1997-2003, data on outpatient use of systemic MLS aggregated at the level of the active substance were collected and expressed in DDD (WHO, version 2004) per 1000 inhabitants per day (DID). Macrolide use was analysed in detail, using a classification based on their mean plasma elimination half-life.

Results: Total outpatient MLS use in 2003 varied by a factor of 11 between the country with the highest (9.36 DID in Greece) and lowest (0.85 DID in Sweden) use. MLS use showed high seasonal variation. Short-, intermediate- and long-acting macrolides were used most in 6, 18 and 1 countries, respectively (mainly erythromycin, clarithromyin and azithromycin, respectively). Lincosamide use was observed in all countries (mainly clindamycin) and substantial streptogramin use only in France (pristinamycin). From 1997 to 2003, MLS use increased in 14 countries and was most pronounced in Greece (increase of >5 DID). Except for Sweden, a relative increase of intermediate- (mainly clarithromycin) and/or long-acting (mainly azithromycin) macrolide use was observed, at the expense of short-acting macrolide (mainly erythromycin) use.

Conclusion: The observed differences between European countries in the levels of MLS use and the extreme seasonal variations in their use suggest that this class of antibiotics is prescribed inappropriately in many countries. The MLS classification developed here facilitates a more comprehensive description of macrolide use in Europe. These data (collected as part of ESAC) could promote investigations that lead to a deeper understanding of the link between macrolide use and resistance.

Keywords: antibiotic use; macrolides; drug consumption; pharmacoepidemiology; ambulatory care; Europe.

{dagger}These authors contributed equally to this work.

{ddagger}Members are listed in the Acknowledgements section.

The originally published version of this article was incorrect. In Table 1, the ATC codes for clindamycin and lindamycin were not complete. The author apologizes for this error.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
S. K. Glass, D. L. Pearl, S. A. McEwen, and R. Finley
Canadian province-level risk factor analysis of macrolide consumption patterns (2000-2006)
J. Antimicrob. Chemother., October 28, 2009; (2009) dkp391v1.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
S. Coenen, A. Muller, N. Adriaenssens, V. Vankerckhoven, E. Hendrickx, H. Goossens, and on behalf of the ESAC Project Group
European Surveillance of Antimicrobial Consumption (ESAC): outpatient parenteral antibiotic treatment in Europe
J. Antimicrob. Chemother., July 1, 2009; 64(1): 200 - 205.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
L. Dong, H. Yan, and D. Wang
Antibiotic prescribing patterns in village health clinics across 10 provinces of Western China
J. Antimicrob. Chemother., August 1, 2008; 62(2): 410 - 415.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
S. S. Richter, K. P. Heilmann, C. L. Dohrn, S. E. Beekmann, F. Riahi, J. Garcia-de-Lomas, M. Ferech, H. Goossens, and G. V. Doern
Increasing telithromycin resistance among Streptococcus pyogenes in Europe
J. Antimicrob. Chemother., March 1, 2008; 61(3): 603 - 611.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
M. Denton, B. O'Connell, P. Bernard, V. Jarlier, Z. Williams, and A. S. Henriksen
The EPISA study: antimicrobial susceptibility of Staphylococcus aureus causing primary or secondary skin and soft tissue infections in the community in France, the UK and Ireland
J. Antimicrob. Chemother., March 1, 2008; 61(3): 586 - 588.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
J. Flamaing, J. Verhaegen, J. Vandeven, N. Verbiest, and W. E. Peetermans
Pneumococcal bacteraemia in Belgium (1994 2004): the pre-conjugate vaccine era
J. Antimicrob. Chemother., January 1, 2008; 61(1): 143 - 149.
[Abstract] [Full Text] [PDF]

Home page
 Qual Saf Health CareHome page
S. Coenen, M. Ferech, F. M Haaijer-Ruskamp, C. C Butler, R. H Vander Stichele, T. J M Verheij, D. L Monnet, P. Little, H. Goossens, and the ESAC Project Group
European Surveillance of Antimicrobial Consumption (ESAC): quality indicators for outpatient antibiotic use in Europe
Qual. Saf. Health Care, December 1, 2007; 16(6): 440 - 445.
[Abstract] [Full Text] [PDF]

Home page
 J. Bacteriol.Home page
C. W. Euler, P. A. Ryan, J. M. Martin, and V. A. Fischetti
M.SpyI, a DNA Methyltransferase Encoded on a mefA Chimeric Element, Modifies the Genome of Streptococcus pyogenes
J. Bacteriol., February 1, 2007; 189(3): 1044 - 1054.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
M. Ferech, S. Coenen, S. Malhotra-Kumar, K. Dvorakova, E. Hendrickx, C. Suetens, H. Goossens, and on behalf of the ESAC Project Group
European Surveillance of Antimicrobial Consumption (ESAC): outpatient antibiotic use in Europe
J. Antimicrob. Chemother., August 1, 2006; 58(2): 401 - 407.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.